Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: gringodoc who wrote (2932)	8/10/1999 11:06:00 AM
From: Marconi	Respond to of 10293

Hello GringoDoc: ZONA and proliferation of brown fat tissue in male rats Hmmmm. Seems the potential issue resulted in a market reaction of Zona falling more than 2 points to near 5 $/sh. The fatuous comment from Zonagen's CEO Podolski, "Phentolamine has been on the market for 50 years," said Joseph S. Podolski, President and Chief Executive Officer of Zonagen. "Given this and the fact that our previous trials showed no abnormalities, we believe we can provide sufficient information to the FDA to remove the clinical hold. has no merit. He needs to clarify the statement so that prior male rat studies have shown no brown fat tissue proliferation as opposed to the implication nothing was seen in previous trials, suggesting that patients have been examined for fatty tissue proliferation and nothing has been found in parallel to the male rat indications. Or separately, that prior male rat studies do not support the latest indication. Such ambiguity is probably worth $2x11.2M shares, or $23M hit to market cap realized today. And rats, I have been hoping for a bouncein recent months to go short. Rats! Rats! Rats! I suppose that might be what Podolski is muttering too. Best regards, m